Risk of atypical femoral fracture during and after bisphosphonate use

New England Journal of Medicine

Volumn 371, Issue 10, 2014, Pages 974-976

  Schilcher, Jörg ^a   Koeppen, Veronika ^a   Aspenberg, Per ^a   Michaëlsson, Karl ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; PROTON PUMP INHIBITOR; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE RADIOGRAPHY; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; HUMAN; LETTER; OSTEOPOROSIS; REGISTER; RISK FACTOR; SEX DIFFERENCE; SWEDISH CITIZEN; TREATMENT DURATION; AGED; CASE CONTROL STUDY; FEMALE; MALE; MIDDLE AGED; RISK;

AGED; CASE-CONTROL STUDIES; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 84907001893     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1403799     Document Type: Letter

References (5)

1. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
2. Gates BJ, Sonnett TE, Duvall CA, Dobbins EK. Review of osteoporosis pharmacotherapy for geriatric patients. Am J Geriatr Pharmacother 2009;7:293-323.
3. Schilcher J, Michalsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37. [Errata, N Engl J Med 2011;365:1551, 2012; 367:582.]
4. Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michalsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features: a comparison of 59 cases and 218 controls. Bone 2013;52:389-92.
5. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.